HUE055051T2 - Eljárás diaril-tiohidantoin és diaril-hidantoin vegyületek szintézisére - Google Patents

Eljárás diaril-tiohidantoin és diaril-hidantoin vegyületek szintézisére

Info

Publication number
HUE055051T2
HUE055051T2 HUE18153287A HUE18153287A HUE055051T2 HU E055051 T2 HUE055051 T2 HU E055051T2 HU E18153287 A HUE18153287 A HU E18153287A HU E18153287 A HUE18153287 A HU E18153287A HU E055051 T2 HUE055051 T2 HU E055051T2
Authority
HU
Hungary
Prior art keywords
diarylthiohydantoin
synthesis
processes
diarylhydantoin compounds
diarylhydantoin
Prior art date
Application number
HUE18153287A
Other languages
English (en)
Hungarian (hu)
Inventor
Andrew Thompson
Carol Lamberson
Scott Greenfield
Rajendra Parasmal Jain
Remy Angelaud
Original Assignee
Medivation Prostate Therapeutics Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medivation Prostate Therapeutics Llc filed Critical Medivation Prostate Therapeutics Llc
Publication of HUE055051T2 publication Critical patent/HUE055051T2/hu

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/86Oxygen and sulfur atoms, e.g. thiohydantoin
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/72Two oxygen atoms, e.g. hydantoin
    • C07D233/74Two oxygen atoms, e.g. hydantoin with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to other ring members
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41661,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00Preparation of carboxylic acid amides
    • C07C231/12Preparation of carboxylic acid amides by reactions not involving the formation of carboxamide groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/28Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
    • C07C237/30Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having the nitrogen atom of the carboxamide group bound to hydrogen atoms or to acyclic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D235/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
HUE18153287A 2010-02-24 2011-02-24 Eljárás diaril-tiohidantoin és diaril-hidantoin vegyületek szintézisére HUE055051T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US30779610P 2010-02-24 2010-02-24

Publications (1)

Publication Number Publication Date
HUE055051T2 true HUE055051T2 (hu) 2021-10-28

Family

ID=44507217

Family Applications (2)

Application Number Title Priority Date Filing Date
HUE11748095A HUE038637T2 (hu) 2010-02-24 2011-02-24 Eljárás a diaril-tiohidantoin és a diaril-hidantoin vegyületek szintetizálására
HUE18153287A HUE055051T2 (hu) 2010-02-24 2011-02-24 Eljárás diaril-tiohidantoin és diaril-hidantoin vegyületek szintézisére

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HUE11748095A HUE038637T2 (hu) 2010-02-24 2011-02-24 Eljárás a diaril-tiohidantoin és a diaril-hidantoin vegyületek szintetizálására

Country Status (17)

Country Link
US (1) US9174943B2 (OSRAM)
EP (2) EP3329775B1 (OSRAM)
JP (1) JP5718372B2 (OSRAM)
KR (1) KR101514659B1 (OSRAM)
CN (1) CN103108549B (OSRAM)
BR (1) BR112012021406B1 (OSRAM)
CA (1) CA2790924C (OSRAM)
CY (2) CY1120207T1 (OSRAM)
DK (2) DK3329775T3 (OSRAM)
ES (2) ES2880354T3 (OSRAM)
HU (2) HUE038637T2 (OSRAM)
MX (1) MX2012009782A (OSRAM)
PL (2) PL3329775T3 (OSRAM)
PT (2) PT2538785T (OSRAM)
RU (1) RU2554081C2 (OSRAM)
SI (2) SI3329775T1 (OSRAM)
WO (1) WO2011106570A1 (OSRAM)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7709517B2 (en) * 2005-05-13 2010-05-04 The Regents Of The University Of California Diarylhydantoin compounds
US8680291B2 (en) 2007-10-26 2014-03-25 The Regents Of The University Of California Diarylhydantoin compounds
AU2011218173C1 (en) * 2010-02-16 2015-04-16 Aragon Pharmaceuticals, Inc. Androgen receptor modulators and uses thereof
BR112013023028B1 (pt) 2011-03-10 2021-09-21 Suzhou Kintor Pharmaceuticals, Inc Composto de fórmula (i) ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica e formulação farmacêutica tópica
WO2013067151A1 (en) * 2011-11-02 2013-05-10 Medivation Prostate Therapeutics, Inc. Treatment methods using diarylthiohydantoin derivatives
CA2884640A1 (en) * 2012-09-11 2014-03-20 Dr. Reddy's Laboratories Limited Enzalutamide polymorphic forms and its preparation
ES2892029T3 (es) * 2012-09-11 2022-02-01 Medivation Prostate Therapeutics Llc Formulaciones de enzalutamida
UA117663C2 (uk) 2012-09-26 2018-09-10 Арагон Фармасьютікалз, Інк. Антиандроген для лікування неметастатичного кастраційно-резистентного раку передміхурової залози
CA2889756C (en) 2012-10-26 2023-03-14 Memorial Sloan-Kettering Cancer Center Thiohydantoin compounds as androgen receptor modulators
JOP20200097A1 (ar) 2013-01-15 2017-06-16 Aragon Pharmaceuticals Inc معدل مستقبل أندروجين واستخداماته
RU2520134C1 (ru) 2013-02-27 2014-06-20 Общество с ограниченной ответственностью "Авионко" (ООО "Авионко") Замещенные (r)-3-(4-метилкарбамоил-3-фторфениламино)-тетрагидро-фуран-3-енкарбоновые кислоты и их эфиры, способ их получения и применения
WO2014167428A2 (en) * 2013-04-10 2014-10-16 Shilpa Medicare Limited Amorphous 4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)-2-fluoro-n-methylbenzamide
WO2015042029A1 (en) * 2013-09-19 2015-03-26 Glaxosmithkline Llc Combination drug therapy
CN106543085A (zh) * 2013-10-14 2017-03-29 杭州普晒医药科技有限公司 恩杂鲁胺的固态形式及其制备方法和用途
US20160251316A1 (en) 2013-10-31 2016-09-01 Sun Pharmaceutical Industries Limited Process for the preparation of enzalutamide
WO2015092617A1 (en) 2013-12-16 2015-06-25 Ranbaxy Laboratories Limited Processes and intermediates for the preparation of enzalutamide
CN104803918B (zh) * 2014-01-26 2017-11-10 上海医药工业研究院 恩杂鲁胺的制备方法
CN104803919A (zh) * 2014-01-26 2015-07-29 上海医药工业研究院 用于制备恩杂鲁胺中间体的方法
US9611225B2 (en) * 2014-01-27 2017-04-04 Cadila Healthcare Limited Process for preparation of androgen receptor antagonist
CN104844521B (zh) * 2014-02-13 2017-08-15 成都伊诺达博医药科技有限公司 抗前列腺癌药物恩杂鲁胺的合成方法
US20170174635A1 (en) 2014-02-13 2017-06-22 Sun Pharmaceutical Industries Limited Process for the preparation of enzalutamide
CN104844520B (zh) * 2014-02-13 2017-09-05 成都伊诺达博医药科技有限公司 一种合成恩杂鲁胺的方法
CZ2014232A3 (cs) 2014-04-07 2015-10-14 Zentiva, K.S. Způsob výroby enzalutamidu
CN103910679B (zh) * 2014-04-23 2016-05-25 杭州新博思生物医药有限公司 一种恩杂鲁胺的制备方法
CN103980141A (zh) * 2014-04-25 2014-08-13 山东大学 恩泽特鲁的合成方法
CN104016924B (zh) * 2014-06-16 2016-04-13 上海鼎雅药物化学科技有限公司 一种“一锅法”合成恩杂鲁胺的方法
RU2557235C1 (ru) 2014-07-08 2015-07-20 Александр Васильевич Иващенко Замещенные 2-тиоксо-имидазолидин-4-оны и их спироаналоги, противораковый активный компонент, фармацевтическая композиция, лекарственный препарат, способ лечения рака простаты
WO2016005875A1 (en) * 2014-07-11 2016-01-14 Shilpa Medicare Limited An improved process for the preparation of enzalutamide
CN105461633A (zh) * 2014-07-31 2016-04-06 江苏豪森药业集团有限公司 恩杂鲁胺的制备方法
CN105367441B (zh) * 2014-08-18 2018-11-06 上海医药工业研究院 用于合成恩杂鲁胺的新化合物
CN105461634A (zh) * 2014-08-19 2016-04-06 江苏豪森药业集团有限公司 恩杂鲁胺的制备方法
WO2016051423A2 (en) * 2014-10-01 2016-04-07 Laurus Labs Private Limited An improved process for the preparation of enzalutamide
CN104356068A (zh) * 2014-10-30 2015-02-18 杭州新博思生物医药有限公司 恩杂鲁胺新晶型及其制备方法
SG10201912805SA (en) * 2014-12-19 2020-02-27 Aragon Pharmaceuticals Inc Process for the preparation of a diarylthiohydantoin compound
ITUB20151204A1 (it) 2015-05-28 2016-11-28 Olon Spa Procedimento per la preparazione di enzalutamide
ITUB20151311A1 (it) * 2015-05-28 2016-11-28 Olon Spa Procedimento per la preparazione di enzalutamide
ITUB20151256A1 (it) 2015-05-28 2016-11-28 Olon Spa Processo industriale per la preparazione di enzalutamide
US10118899B2 (en) 2015-05-29 2018-11-06 Astellas Pharma, Inc. Production method of enzalutamide crystal form
TWI613194B (zh) * 2015-06-10 2018-02-01 台灣神隆股份有限公司 用於製備恩雜魯胺的新穎方法
CN105330560A (zh) * 2015-10-13 2016-02-17 福格森(武汉)生物科技股份有限公司 一种恩杂鲁胺中间体的制备方法
TWI726969B (zh) 2016-01-11 2021-05-11 比利時商健生藥品公司 用作雄性激素受體拮抗劑之經取代之硫尿囊素衍生物
CN107954936B (zh) * 2016-10-17 2021-03-19 海创药业股份有限公司 一种制备氘代咪唑二酮类化合物的方法
CN108069869B (zh) * 2016-11-09 2022-03-01 上海医药工业研究院 一种Apalutamide的制备方法及其中间体
TW201831461A (zh) * 2017-01-18 2018-09-01 台灣神隆股份有限公司 製備阿帕魯醯胺的方法
EP3616696B1 (en) 2017-04-28 2025-03-05 Astellas Pharma Inc. Orally administrable enzalutamide-containing pharmaceutical composition
CN107501237B (zh) * 2017-08-17 2022-03-22 上海西浦医药科技有限公司 一种Apalutamide的合成方法
US10702508B2 (en) 2017-10-16 2020-07-07 Aragon Pharmaceuticals, Inc. Anti-androgens for the treatment of non-metastatic castration-resistant prostate cancer
HUE064356T2 (hu) * 2017-11-28 2024-03-28 Aarti Pharmalabs Ltd Eljárás enzalutamid elõállítására új intermedier felhasználásával
CN108047200A (zh) * 2017-12-05 2018-05-18 上海丰瑞医药科技有限公司 一种二芳基乙内酰硫脲类化合物的制备方法及其中间体
CN109988077A (zh) * 2017-12-29 2019-07-09 上海法默生物科技有限公司 一种阿帕鲁胺的合成方法及中间体
CN110872258B (zh) * 2018-09-04 2021-05-25 北京凯莱天成医药科技有限公司 一种前列腺癌药物恩杂鲁胺的制备工艺
CN109651256A (zh) * 2018-11-20 2019-04-19 上海健康医学院 一种式(viii)的恩杂鲁胺的制备方法
CN109503416A (zh) * 2018-12-24 2019-03-22 常州智超化学有限公司 一种恩杂鲁胺中间体合成方法
CN112047888B (zh) * 2019-06-05 2024-08-02 安礼特(上海)医药科技有限公司 一种合成恩杂鲁胺的方法
CN111320552B (zh) * 2020-02-28 2023-10-27 江西科睿药业有限公司 一种恩扎卢胺中间体的制备方法
US12152035B2 (en) 2020-12-30 2024-11-26 Industrial Technology Research Institute Androgen receptor binding molecule and use thereof
CN117120436A (zh) * 2021-03-30 2023-11-24 苏州开拓药业股份有限公司 一种一步法合成乙内酰硫脲衍生物的方法
EP4112603A1 (en) 2021-06-29 2023-01-04 Química Sintética, S.A. Processes for the preparation of non-steroidal antiandrogens
CN115572264B (zh) * 2021-07-06 2025-12-05 山东新时代药业有限公司 一种恩杂鲁胺的制备方法
CN113698310B (zh) * 2021-08-20 2023-03-17 江西金丰药业有限公司 一种恩杂鲁胺双酯中间体的制备方法
CN114591246A (zh) * 2022-03-25 2022-06-07 重庆华邦制药有限公司 一种恩扎卢胺的纯化方法
CN114907439B (zh) * 2022-06-29 2023-07-21 云南中医药大学 一种抗癌化合物及其制药用途
CN115181043B (zh) * 2022-07-27 2024-05-07 爱斯特(成都)生物制药股份有限公司 一种连续流制备4-异硫氰基-2-(三氟甲基)苯甲腈的方法
CN115611765A (zh) * 2022-09-30 2023-01-17 重庆华邦胜凯制药有限公司 一种恩扎卢胺中间体的制备方法
CN115536634B (zh) * 2022-10-17 2024-06-11 上海博悦生物科技有限公司 一种阿帕他胺的合成方法
CN115724759B (zh) * 2022-11-23 2024-06-25 爱斯特(成都)生物制药股份有限公司 一种恩扎卢胺中间体的制备方法
CN117645572A (zh) * 2023-11-23 2024-03-05 奥锐特药业股份有限公司 恩扎卢胺及其中间体的制备方法
CN118496163B (zh) * 2024-05-08 2025-02-25 奥锐特药业股份有限公司 一种恩扎卢胺及其中间体的制备方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2884448A (en) * 1956-07-02 1959-04-28 Gen Aniline & Film Corp Hydrolysis of n-substituted amides
DE1906492B2 (de) * 1969-02-10 1980-07-31 Bayer Ag, 5090 Leverkusen Carbonsäure-Derivate enthaltende Hydantoine und Polyhydantoine
US4424396A (en) * 1982-07-21 1984-01-03 Occidental Chemical Corporation Process for the preparation substituted anilino acids
FR2693461B1 (fr) * 1992-07-08 1994-09-02 Roussel Uclaf Nouvelles phénylimidazolidines substituées, leur procédé de préparation, leur application comme médicaments et les compositions pharmaceutiques les renfermant.
US5235093A (en) * 1992-01-27 1993-08-10 Monsanto Company Process for preparing carboxylic amide ester
FR2823209B1 (fr) 2001-04-04 2003-12-12 Fournier Lab Sa Nouvelles thiohydantoines et leur utilisation en therapeutique
RU2206326C2 (ru) 2001-04-10 2003-06-20 Асафов Александр Виленович Применение натрия нуклеоспермата для лечения вич-инфекции и способ лечения
KR20070106969A (ko) * 2004-09-09 2007-11-06 추가이 세이야쿠 가부시키가이샤 신규 이미다졸리딘 유도체 및 그 용도
US7709517B2 (en) 2005-05-13 2010-05-04 The Regents Of The University Of California Diarylhydantoin compounds
RS53967B1 (sr) * 2005-05-13 2015-08-31 The Regents Of The University Of California Diaril hidantoin jedinjenja kao antagonisti receptora androgena za lečenje raka
LT2656841T (lt) 2006-03-27 2016-09-26 The Regents Of The University Of California Androgeno receptoriaus moduliatorius, skirtas prostatos vėžio ir su androgeno receptoriumi susijusių ligų gydymui
MX2008012492A (es) * 2006-03-29 2008-12-12 Univ California Compuestos de diariltiohidantoina.
WO2008093838A1 (ja) 2007-02-01 2008-08-07 Chugai Seiyaku Kabushiki Kaisha スルファモイル基を有するピリジルイミダゾリジン誘導体、およびその医薬としての使用
WO2008119015A2 (en) * 2007-03-27 2008-10-02 Sloan-Kettering Institute For Cancer Research Synthesis of thiohydantoins
US8680291B2 (en) 2007-10-26 2014-03-25 The Regents Of The University Of California Diarylhydantoin compounds
JP2011506533A (ja) * 2007-12-20 2011-03-03 エフ.ホフマン−ラ ロシュ アーゲー Mekキナーゼ阻害剤としての置換ヒダントイン
BRPI1007990A2 (pt) 2009-02-24 2015-09-01 Medivation Prostate Therapeutics Inc Compostos específicos de diaril-hidantoína e diariltioidantoína.
EP2416657A4 (en) * 2009-04-09 2012-09-05 Medivation Prostate Therapeutics Inc COMPOUNDS COMPRISING SUBSTITUTED DI-ARYLHYDANTOIDS AND DI-ARYLTHIOHYDANTOINES AND METHODS OF USE THEREOF

Also Published As

Publication number Publication date
BR112012021406A8 (pt) 2018-07-31
BR112012021406B1 (pt) 2021-08-10
PT2538785T (pt) 2018-05-09
JP5718372B2 (ja) 2015-05-13
PT3329775T (pt) 2021-07-19
EP3329775A1 (en) 2018-06-06
US9174943B2 (en) 2015-11-03
MX2012009782A (es) 2012-11-29
RU2554081C2 (ru) 2015-06-27
KR20130027468A (ko) 2013-03-15
ES2671343T3 (es) 2018-06-06
HUE038637T2 (hu) 2018-12-28
CA2790924A1 (en) 2011-09-01
JP2013520519A (ja) 2013-06-06
EP2538785A1 (en) 2013-01-02
EP3329775B1 (en) 2021-04-21
CN103108549B (zh) 2015-09-09
CY1124334T1 (el) 2022-07-22
BR112012021406A2 (pt) 2018-06-05
DK2538785T3 (en) 2018-05-22
SI2538785T1 (en) 2018-05-31
PL3329775T3 (pl) 2021-11-08
SI3329775T1 (sl) 2021-09-30
RU2012140454A (ru) 2014-03-27
KR101514659B1 (ko) 2015-04-23
EP2538785B1 (en) 2018-03-21
CY1120207T1 (el) 2018-12-12
EP2538785A4 (en) 2013-10-30
CN103108549A (zh) 2013-05-15
WO2011106570A1 (en) 2011-09-01
US20130190507A1 (en) 2013-07-25
PL2538785T3 (pl) 2018-08-31
ES2880354T3 (es) 2021-11-24
CA2790924C (en) 2016-08-02
DK3329775T3 (da) 2021-07-26

Similar Documents

Publication Publication Date Title
SI3329775T1 (sl) Procesi za sintezo spojin diariltiohidantoina in diarilhidantoina
EP2552874A4 (en) PROCESS FOR PREPARING HEXAFLUOR-2 BUTENE
IL221170A0 (en) Processes of synthesizing dihydropyridophthalazinone derivatives
GB201301533D0 (en) Process for the synthesis and purification of oxycodone
EP2558432A4 (en) METHOD FOR THE PRODUCTION OF TETRAFLUOROLEFINES
IL220936A0 (en) Process for the synthesis of lacosamide
ZA201208672B (en) Process for the preparation of synthesis gas
IL214437A0 (en) Process for the synthesis of cleistanthin
IL222474A0 (en) Method of synthesis
EP2576556A4 (en) PROCESS FOR SYNTHESIZING CARBONUCLEOSIDE AND PARTICIPATING INTERMEDIATES
EP2596007A4 (en) PROCESS FOR THE PREPARATION OF 17-DEOXY-CORTICOSTEROIDS
IL223926A0 (en) Synthesis of cyclopentaquinazolines
ZA201300546B (en) Process for the preparation of 3-haloalkylpyrazoles
GB201000971D0 (en) Process for the convertion of synthesis gas
IL225747A (en) A process for making cyclic carbamates
EP2616430A4 (en) NOVEL PHENOXYISOBUTYRIC ACID COMPONENTS AND METHODS OF SYNTHESIS
GB201020357D0 (en) Compounds and methods of making the same
IL225708A0 (en) Methods for the synthesis of scylitol and related compounds
PL2556040T3 (pl) Przemysłowy sposób syntezy (s)-(+)-pregabaliny
PT2390246T (pt) Processo para a preparação de aminaftona
PL2598504T3 (pl) Sposób otrzymywania dimiracetamu
GB201007519D0 (en) Means for inhibiting the expression of rragb
IL224304A (en) A process for making dichlorobulben
ZA201208995B (en) Method of synthesis
GB0904311D0 (en) Processes for the preparation of compounds